AveXis gains after revealing SMA study details

Gene therapy company AveXis Inc. (NASDAQ:AVXS) added $10.65 (22%) to $58.66 after it announced the design of a planned pivotal study of AVXS-101 to treat

Read the full 250 word article

User Sign In